

****Published July 2018****

MarketVIEW: Lassa fever vaccines (CAT: VAMV080)

Product Name	:	MarketVIEW: Lassa fever vaccines
Description	:	Global vaccine commercial opportunity assessment
Contents	:	Executive presentation (~100 slides.pdf) + MS-Excel forecast model(s) (.xls)
Therapeutic Area	:	Lassa fever vaccines
Publication date	:	July 2018
Catalogue No	:	VAMV080

Background

Lassa fever is an acute viral hemorrhagic illness caused by **Lassa virus (LASV)**, a single-stranded RNA virus of the *Arenaviridae* family. The virus is zoonotic and mainly transmitted from the host, *M natalensis* (multimammate rat) to humans where it can cause symptoms ranging from fever, general malaise, weakness, and headache to the more serious outcomes of multi-organ failure or death. A significant cause of morbidity in survivors is deafness (which can be permanent) and occurs in approximately one-third of cases.

It is estimated that there are between 100,000 and 300,000 Lassa fever infections in West Africa per year, resulting in approximately 5,000 deaths, although estimates are outdated and impacted by a lack of routine surveillance. Intravenous ribavirin (if given early) can reduce mortality. There are a number of prophylactic Lassa fever vaccines in pre-clinical development supported by CEPI/WHO initiatives but none yet in clinical stages.

This **MarketVIEW** product is a comprehensive Executive Presentation (~100 slides) and MS-Excel forecast model which investigates the commercial potential of a putative Lassa fever vaccine in all relevant target groups (preventative and emergency scenarios) to 2030. There is a detailed case study analysis of Ebola vaccine procurement/deployment to serve as guidance with all assumptions clearly outlined. A thorough review of current disease background/epidemiology and R&D competitive environment are also included. This product is ideally suited to organisations wishing to quantify the Lassa fever vaccine opportunity.

Methodology

VacZine Analytics has closely monitored all significant source material pertaining to Lassa fever vaccines in each respective market. Source materials used are literature articles, government websites, medical bodies and associations, conference proceedings etc. Previously published research by **VacZine Analytics** in the field of viral based-pathogens, especially Ebola virus has also been utilised.

PRODUCT CONTENTS:

Published July 2018 (CAT No: VAMV080)

****This product is a [summary presentation \(.pdf\)](#), [a forecast model \(.xls\)](#)

Contents – Summary presentation (.pdf)¹

Contents
Author's notes
Executive summary
[SECTION 1] Lassa fever vaccines: key commercial model outputs
[SECTION 2] Lassa fever: disease background
[SECTION 3] Lassa fever: epidemiology
[SECTION 4] Lassa fever: summary of vaccine development
[SECTION 5] Lassa fever vaccines: modelling commercial potential
About **VacZine Analytics**
Disclaimer



SNAPSHOT

PAGES: ~100 slides fully referenced/sourced. Available in .pdf form

Contents – Vaccine demand model (MS Excel-based)

Worksheets = >30 interconnected

¹ Full contents i.e. title per slide is available upon request

PRODUCT COST:

VacZine Analytics will grant a [enter region] license to [enter client name], for the price of:

- FULL PRODUCT - USD **\$6,995.00**/ GBP **£5380.00**# (Region license)*

*A region is North America, Europe or ROW

For orders in the UK, VAT at 20% will be added to final invoice total

- *indicative prevailing rate will be applied on date of transaction, third party licenses may be restricted/vary*

HOW TO ORDER:

To order please contact your region account manager or order direct at orders@vaczine-analytics.com This report can also be purchased on-line. Please review the **TERMS and CONDITIONS** of purchase.




VacZine Analytics © is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics © and the “**spiral logo**” are UK Registered Trademarks, 2009

BIBLIOGRAPHY

References – available upon request



TERMS and CONDITIONS:

VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as “The Company”). (Herein [enter client name] to as “The Client”).

1. All Rights Reserved. This finished research product is a licensed product. It may not be reproduced, stored in a retrieval system or transmitted in any form without the written permission of the Company **VacZine Analytics** (of division of Assay Advantage Ltd).
2. The license granted by the Company to the Client will be non-exclusive, non-transferable and should only be used for the Client business purposes at the agreed Client sites/location in accordance with this agreement. The Client will have no ownership rights over the research product.
3. Invoicing will **100%** after submission of the deliverables (.pdf) and (.xls) to the Client.
4. If not purchased on line invoices are payable within **thirty days** of the invoice date.
5. All proposals are quoted in **\$USD dollars or £GBP or €euro** and invoices are to be settled in the same currency.
6. The Company agrees not to disclose to any third party confidential information acquired in the course of providing the research product listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company’s employees and agents with the performance of the Company’s obligations to achieve satisfactory completion of the project and approved in writing by the Client.
7. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
8. Please also refer to Master **TERMS and CONDITIONS** available upon request.

VacZine Analytics

A division of Assay Advantage Ltd

Warren House

Bells Hill

Bishops Stortford

Herts

CM23 2NN

United Kingdom

Tel: +44 (0) 1279 654514 / +44 (0) 7952470582 / Fax: +44 (0) 1279 927049

E-mail: info@vaczine-analytics.com

About VacZine Analytics:

VacZine Analytics is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information, please visit our website www.vacZine-analytics.com

VacZine Analytics © is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics © and “the spiral logo” are UK Registered Trademarks, 2009

